Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trialJeffrey A. Jones, John C. Byrd, Richard R. Furman et al.|The Lancet Oncology|2017Cited by 378
Preliminary Results of a Phase 2, Open-Label Study of Venetoclax (ABT-199/GDC-0199) Monotherapy in Patients with Chronic Lymphocytic Leukemia Relapsed after or Refractory to Ibrutinib or Idelalisib TherapyJeffrey A. Jones, John C. Byrd, Anthony R. Mato et al.|Blood|2015Cited by 36
Analysis of PET-CT to Identify Richter's Transformation in 167 Patients with Disease Progression Following Kinase Inhibitor TherapyAnthony R. Mato, Jeffrey A. Jones, William G. Wierda et al.|Blood|2017Cited by 18